CN114225103A - Amnion-graphene oxide hydrogel medical biological dressing - Google Patents
Amnion-graphene oxide hydrogel medical biological dressing Download PDFInfo
- Publication number
- CN114225103A CN114225103A CN202111664317.1A CN202111664317A CN114225103A CN 114225103 A CN114225103 A CN 114225103A CN 202111664317 A CN202111664317 A CN 202111664317A CN 114225103 A CN114225103 A CN 114225103A
- Authority
- CN
- China
- Prior art keywords
- graphene oxide
- amnion
- mixed solution
- biological dressing
- medical biological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/108—Elemental carbon, e.g. charcoal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Abstract
The invention discloses an amnion-graphene oxide hydrogel medical biological dressing which is divided into an upper layer and a lower layer, wherein the upper layer is formed by cross-linking SA and AM, the lower layer is formed by cross-linking SA, HA and GO, and the preparation method comprises the following steps: (1) dropping hydroxyapatite into a sodium alginate aqueous solution, and then dropping graphene oxide to obtain a mixed solution A; (2) adding the amnion powder into the sodium alginate aqueous solution, and uniformly mixing to obtain a mixed solution B; pouring the mixed solution B into the mixed solution A, and adding CaCl2And (4) crosslinking the solution to obtain the product. The amnion-graphene oxide hydrogel medical biological dressing has the effects of stopping bleeding, resisting bacteria, diminishing inflammation, accelerating wound healing, reducing scar generation and the like, has good hygroscopicity and air permeability, can reduce the times of dressing replacement, reduce the cost and save the nursing time, and can be used as or for preparing a medicine for promoting wound healing.
Description
Technical Field
The invention relates to an amnion-graphene oxide hydrogel medical biological dressing, and belongs to the technical field of medical biological dressings.
Background
Chronic intractable wound surface causes continuous infection of wound surface and accompanied chronic inflammation due to complex internal and external factors, and is difficult to heal for a long time, which brings great trouble to patients and medical workers. Research shows that the surface of the wound surface forms a biological membrane due to bacterial adhesion, and the biological membrane is not sensitive to antibiotics, but can continuously worsen the condition of the wound surface, which is the main reason for chronic intractable wound surfaces.
The traditional dressing (such as gauze) is easy to adhere to the wound tissue, and can cause secondary damage to the wound during dressing change, thereby not only increasing the pain of patients, but also causing great troubles to the operation of medical staff. In addition, the traditional dressing also has the defects of high wound infection probability, slow healing and the like, and can not meet the wound nursing requirements of people gradually. In 1962, Winter et al proposed the theory of "moist wound healing". The theory indicates that under the wet healing environment close to the physiological state, the wound does not scab, the growth of granulation is facilitated, the skin cell division is facilitated, and the wound healing speed is 2 times of that of the dry environment. Therefore, biological dressings developed on the basis of this theory are becoming more and more popular. The hydrogel as a novel medical dressing can absorb the exudate of a wound surface, keep the humidity of the wound surface and reduce the adhesion with tissues. In addition, the hydrogel has a semi-permeable membrane structure that allows for the exchange of oxygen and water vapor while providing a barrier to dust and bacteria in the environment.
Sodium Alginate (SA) is a polysaccharide high molecular polymer, and can be mixed with divalent metal cation (Ca)2+、Fe2+、Cu2+) The hydrogel formed by crosslinking not only has good hydrophilicity, biocompatibility and biodegradability, but also has the functions of no toxicity, hemostasis, antibiosis, wound healing promotion and the like.
Amnion (AM) is part of human placenta tissue, and has the advantages of convenient source, easily-accessible raw materials, and low cost. The amnion has very low antigenicity and mild nonspecific antiviral and antibacterial effects, and contains various proteases which can inhibit the inflammation of the wound surface, promote the healing of the wound surface and reduce the scar formation. Amnion, due to its excellent properties, has found increasing use in regenerative medicine, particularly wound repair, as a biological dressing in addition to cytokine donors.
Graphene Oxide (GO) has better antibacterial performance and biocompatibility, and the mechanical strength and hydrophilicity of the material can be improved by adding graphene oxide into a polymer. Researches show that the graphene oxide can increase cell attachment and improve cell functions and behaviors, and can be used as a cell growth promoter.
Hydroxyapatite (HA), the main inorganic component in human and animal bones, can chemically bond with body tissues and release ions harmless to the body, participate in metabolism and promote the repair of damaged tissues.
Disclosure of Invention
Aiming at the prior art, in order to make up the defects of the traditional medical dressing, reduce the infection risk of the chronic refractory wound in the healing process and promote the healing of the wound, the invention provides the amnion-graphene oxide hydrogel medical biological dressing, also provides a preparation method thereof and application thereof in preparing a medicament for promoting the healing of the wound. According to the invention, Sodium Alginate (SA), Hydroxyapatite (HA), Graphene Oxide (GO) and amniotic membrane powder (AM) are used as raw materials, and the amniotic membrane-graphene oxide hydrogel medical biological dressing is finally prepared by researching the combination mode and the proportion of the raw materials.
The invention is realized by the following technical scheme:
an amnion-graphene oxide hydrogel medical biological dressing is prepared by the following method:
(1) dropping hydroxyapatite into sodium alginate water solution while stirring to mix completely and uniformly; then, dropwise adding graphene oxide, stirring while dropwise adding until the graphene oxide and the graphene oxide are completely and uniformly mixed, and obtaining a mixed solution A;
(2) pulverizing amnion, sieving (80 mesh) to obtain amnion powder, adding amnion powder into sodium alginate aqueous solution, and mixing to obtain mixed solution B; pouring the mixed solution B into the mixed solution A, and adding excessive CaCl2Crosslinking the solution for 20-28 hours to obtain the amnion-graphene oxide hydrogel medical biological dressing, soaking the amnion-graphene oxide hydrogel medical biological dressing in 75% (volume concentration) medical alcohol for 12 hours, irradiating the amnion-graphene oxide hydrogel medical biological dressing with ultraviolet rays for sterilization, and then using sterile CaCl2And repeatedly cleaning the solution for 3-5 times, and standing for later use.
Further, in the mixed solution A, the concentration of hydroxyapatite is 3% -7% (w/v, unit g/ml, the same below), the concentration of sodium alginate is 1% -3%, and the concentration of graphene oxide is 0.5% -1.5%.
In the mixed solution B, the concentration of the amniotic membrane powder is 0.5-1.5%, and the concentration of the sodium alginate is 1-3%.
The CaCl is2The concentration of the solution is 0.5-2.0%.
The amnion-graphene oxide hydrogel medical biological dressing is divided into an upper layer and a lower layer, the upper layer is formed by cross-linking SA and AM, the lower layer is formed by cross-linking SA, HA and GO, the amnion-graphene oxide hydrogel medical biological dressing HAs the effects of stopping bleeding, resisting bacteria, diminishing inflammation, accelerating wound healing, reducing scar generation and the like, HAs good hygroscopicity and air permeability, can reduce the times of dressing replacement, reduce the cost and save the nursing time, and can be used as or for preparing medicines for promoting wound healing.
The amnion-graphene oxide hydrogel medical biological dressing takes sodium alginate, hydroxyapatite, graphene oxide and amnion powder as raw materials, and makes up the limitation and the defect of using a single material; the raw materials are nontoxic and harmless to organisms, and have the functions of stopping bleeding, diminishing inflammation, resisting bacteria, promoting wound healing, reducing scar generation and the like. When the amnion-graphene oxide hydrogel medical biological dressing is used, the amnion-graphene oxide hydrogel medical biological dressing has good hygroscopicity and air permeability, the number of times of dressing replacement can be reduced, the pain of a patient is relieved, the cost is reduced, the nursing time is saved, and the operation difficulty of medical workers is reduced.
The invention optimizes the defects of susceptibility to infection, slow wound healing, easy tissue adhesion and the like of the traditional dressing, provides a good solution for the problems of susceptibility to infection, difficult healing and the like of the chronic refractory wound, and has the following advantages and beneficial effects:
1. has good hygroscopicity and air permeability, can reduce the times of dressing change, reduce the cost and save the nursing time.
2. By adopting the design of a 'moist healing theory', the Chinese medicinal composition does not adhere to tissues, does not damage granulation tissues, does not cause pain, relieves the pain of patients in dressing change, and reduces the operation difficulty of medical workers.
3. Simple preparation process, mild condition and no toxicity and harm to organisms.
4. Has hemostatic, antibacterial, antiinflammatory, wound healing promoting, and scar formation reducing effects.
The various terms and phrases used herein have the ordinary meaning as is well known to those skilled in the art.
Drawings
FIG. 1: the lower layer material was mixed (photograph).
FIG. 2: upper layer material mix (photo).
FIG. 3: a photograph of the amnion-graphene oxide hydrogel medical biological dressing.
FIG. 4: a photo of the amnion-graphene oxide hydrogel medical biological dressing, wherein A: a front side; b: a side surface; c: and a back surface.
Detailed Description
The present invention will be further described with reference to the following examples. However, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention.
The instruments, reagents, materials and the like used in the following examples are conventional instruments, reagents, materials and the like in the prior art and are commercially available in a normal manner unless otherwise specified. Unless otherwise specified, the experimental methods, detection methods, and the like described in the following examples are conventional experimental methods, detection methods, and the like in the prior art.
EXAMPLE preparation of amniotic Membrane-graphene oxide hydrogel medical Biodressing
The method comprises the following steps:
(1) dropping hydroxyapatite into sodium alginate water solution while stirring to mix completely and uniformly; then, dropwise adding graphene oxide, stirring while dropwise adding until the graphene oxide and the graphene oxide are completely and uniformly mixed, and obtaining a mixed solution A; the mixed solution A was poured into a mold having a diameter of 3cm (as shown in FIG. 1) to have a thickness of about 1 mm.
In the mixed solution A, the concentration of hydroxyapatite is 5%, the concentration of sodium alginate is 2%, and the concentration of graphene oxide is 1%.
(2) Pulverizing amnion, sieving (80 mesh) to obtain amnion powder, adding amnion powder into sodium alginate aqueous solution, and mixing to obtain mixed solution B; pouring the mixed solution B above the mixed solution A to a thickness of about 1mm (as shown in FIG. 2), and adding excessive CaCl2Crosslinking the solution for 24 hr to obtain amnion-graphene oxide hydrogel medical biological dressing (shown in figure 3), taking out, soaking in 75% (volume concentration) medical alcohol for 12 hr, irradiating with ultraviolet for sterilization, and sterilizing with sterile CaCl2The solution is repeatedly washed for 3-5 times, and is placed (as shown in figure 4) for standby.
In the mixed solution B, the concentration of the amniotic membrane powder is 1 percent, and the concentration of the sodium alginate is 2 percent.
The CaCl is2The concentration of the solution was 1%.
The prepared amnion-graphene oxide hydrogel medical biological dressing is circular, HAs a diameter of 3cm, is divided into an upper layer and a lower layer, the upper layer is formed by crosslinking 2% of SA and 1% of AM, the thickness of the upper layer is about 1mm, the lower layer is formed by crosslinking 2% of SA, 5% of HA and 1% of GO, the thickness of the lower layer is about 1mm, and the amnion-graphene oxide hydrogel medical biological dressing HAs the effects of stopping bleeding, resisting bacteria, diminishing inflammation, accelerating wound healing, reducing scar generation and the like.
The above examples are provided to those of ordinary skill in the art to fully disclose and describe how to make and use the claimed embodiments, and are not intended to limit the scope of the disclosure herein. Modifications apparent to those skilled in the art are intended to be within the scope of the appended claims.
Claims (10)
1. A preparation method of the amnion-graphene oxide hydrogel medical biological dressing is characterized by comprising the following steps:
(1) dropping hydroxyapatite into sodium alginate water solution while stirring to mix completely and uniformly; then, dropwise adding graphene oxide, stirring while dropwise adding until the graphene oxide and the graphene oxide are completely and uniformly mixed, and obtaining a mixed solution A;
(2) pulverizing and sieving amnion to obtain amnion powder, adding amnion powder into sodium alginate aqueous solution, and mixing to obtain mixed solution B; pouring the mixed solution B into the mixed solution A, and adding excessive CaCl2And crosslinking the solution for 20-28 hours to obtain the amnion-graphene oxide hydrogel medical biological dressing.
2. The method for preparing the amnion-graphene oxide hydrogel medical biological dressing according to claim 1, wherein the method comprises the following steps: in the mixed solution A, the concentration of the hydroxyapatite is 3-7%.
3. The method for preparing the amnion-graphene oxide hydrogel medical biological dressing according to claim 1, wherein the method comprises the following steps: in the mixed solution A, the concentration of the sodium alginate is 1-3%.
4. The method for preparing the amnion-graphene oxide hydrogel medical biological dressing according to claim 1, wherein the method comprises the following steps: in the mixed solution A, the concentration of the graphene oxide is 0.5-1.5%.
5. The method for preparing the amnion-graphene oxide hydrogel medical biological dressing according to claim 1, wherein the method comprises the following steps: in the mixed solution B, the concentration of the amniotic membrane powder is 0.5-1.5%.
6. The method for preparing the amnion-graphene oxide hydrogel medical biological dressing according to claim 1, wherein the method comprises the following steps: in the mixed solution B, the concentration of the sodium alginate is 1-3%.
7. The method for preparing the amnion-graphene oxide hydrogel medical biological dressing according to claim 1, wherein the method comprises the following steps: the CaCl is2The concentration of the solution is 0.5-2.0%.
8. The method for preparing the amnion-graphene oxide hydrogel medical biological dressing according to claim 1, wherein the method comprises the following steps: soaking in 75% medical ethanol for 12 hr, sterilizing by irradiating with ultraviolet, and sterilizing with sterile CaCl2And repeatedly cleaning the solution for 3-5 times, and standing for later use.
9. The amnion-graphene oxide hydrogel medical biological dressing prepared by the preparation method of any one of claims 1-8 is divided into an upper layer and a lower layer, wherein the upper layer is formed by cross-linking SA and AM, and the lower layer is formed by cross-linking SA, HA and GO.
10. The use of the amniotic membrane-graphene oxide hydrogel medical biological dressing according to claim 9 as or in the preparation of a medicament for promoting wound healing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111664317.1A CN114225103A (en) | 2021-12-31 | 2021-12-31 | Amnion-graphene oxide hydrogel medical biological dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111664317.1A CN114225103A (en) | 2021-12-31 | 2021-12-31 | Amnion-graphene oxide hydrogel medical biological dressing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114225103A true CN114225103A (en) | 2022-03-25 |
Family
ID=80745284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111664317.1A Pending CN114225103A (en) | 2021-12-31 | 2021-12-31 | Amnion-graphene oxide hydrogel medical biological dressing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114225103A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103483617A (en) * | 2013-10-16 | 2014-01-01 | 苏州大学 | Method for preparing medical bacteriostasis type graphene oxide porous composite material |
| US20170203004A1 (en) * | 2014-10-02 | 2017-07-20 | Wake Forest University Health Sciences | Amniotic membrane powder and its use in wound healing and tissue engineering constructs |
| CN107137768A (en) * | 2017-04-12 | 2017-09-08 | 苏州诺普再生医学有限公司 | A kind of preparation method of de- cell amnion powder |
| CN107441547A (en) * | 2016-05-30 | 2017-12-08 | 四川大学华西医院 | A kind of wound repair material and its production and use |
| CN109395154A (en) * | 2018-11-06 | 2019-03-01 | 东北林业大学 | A kind of high porosity carries the preparation method of medicine wound dressing |
| CN109793920A (en) * | 2019-03-22 | 2019-05-24 | 华南农业大学 | A kind of collagen dressing of the microballoon containing PCL and preparation method thereof and 3D printing application |
| KR20190102564A (en) * | 2018-02-26 | 2019-09-04 | 주식회사 엔도비전 | Multi-layer dressing material for wound treatment |
-
2021
- 2021-12-31 CN CN202111664317.1A patent/CN114225103A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103483617A (en) * | 2013-10-16 | 2014-01-01 | 苏州大学 | Method for preparing medical bacteriostasis type graphene oxide porous composite material |
| US20170203004A1 (en) * | 2014-10-02 | 2017-07-20 | Wake Forest University Health Sciences | Amniotic membrane powder and its use in wound healing and tissue engineering constructs |
| CN107441547A (en) * | 2016-05-30 | 2017-12-08 | 四川大学华西医院 | A kind of wound repair material and its production and use |
| CN107137768A (en) * | 2017-04-12 | 2017-09-08 | 苏州诺普再生医学有限公司 | A kind of preparation method of de- cell amnion powder |
| KR20190102564A (en) * | 2018-02-26 | 2019-09-04 | 주식회사 엔도비전 | Multi-layer dressing material for wound treatment |
| CN109395154A (en) * | 2018-11-06 | 2019-03-01 | 东北林业大学 | A kind of high porosity carries the preparation method of medicine wound dressing |
| CN109793920A (en) * | 2019-03-22 | 2019-05-24 | 华南农业大学 | A kind of collagen dressing of the microballoon containing PCL and preparation method thereof and 3D printing application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | Recent progress of collagen, chitosan, alginate and other hydrogels in skin repair and wound dressing applications | |
| Gruppuso et al. | Polymeric wound dressings, an insight into polysaccharide-based electrospun membranes | |
| Nguyen et al. | Biomedical materials for wound dressing: Recent advances and applications | |
| CN111228040B (en) | Absorbable anti-adhesion dressing and preparation method thereof | |
| CN102657893A (en) | Medical nano-fiber sponge material and preparation method and application thereof | |
| Hawthorne et al. | Enhancing wound healing dressing development through interdisciplinary collaboration | |
| CN115124738B (en) | Double-layer bionic drug-loaded hydrogel and preparation and application thereof | |
| Watson et al. | Wound dressings | |
| CN106110369B (en) | A kind of medical composite type hyaluronic acid dressing and preparation method thereof | |
| CN113511811A (en) | Multifunctional mesoporous biomaterial, preparation method and application | |
| CN110876814A (en) | Liquid band-aid rich in antibacterial peptide and preparation method thereof | |
| Lin et al. | Amnion overlay meshed skin autograft | |
| Gupta et al. | Calcium alginate in the management of acute surgical wounds and abscesses | |
| CN114225103A (en) | Amnion-graphene oxide hydrogel medical biological dressing | |
| CN112245648B (en) | Anti-inflammatory and antibacterial hydrocolloid oily yarn and preparation method thereof | |
| CN107982568A (en) | Degradable biological auxiliary material and its preparation method and application | |
| Wójcik et al. | Bioactive curdlan/agarose dressing enriched with gentamicin for infected wounds–pilot studies | |
| CN110251716B (en) | Gel dressing for wound care and preparation method thereof | |
| TWI247614B (en) | Wound dressing | |
| Sonar et al. | A Comprehensive review on wound dressing usage in clinical settings | |
| CN112274687B (en) | Stable hydrocolloid oil yarn and preparation method thereof | |
| CN108992699A (en) | A kind of functional Wound dressing and preparation method thereof containing active composite material | |
| Delia et al. | Dressings and dermal substitutes | |
| JP2004523521A (en) | Promotion of cell regeneration and / or cell differentiation using non-metabolizable carbohydrates and polymer absorbents | |
| CN108144100A (en) | A kind of Wound dressing for promoting wound healing and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220325 |
|
| WD01 | Invention patent application deemed withdrawn after publication |